This article first appeared on GuruFocus .
Release Date: August 06, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Cresco Labs Inc ( CRLBF ) delivered strong Q2 2026 results with revenue of $173 million, up 15% sequentially, and adjusted EBITDA of $40 million, up 20% sequentially, demonstrating solid operating leverage.
-
The company's strategic M&A in Pennsylvania is immediately accretive, with the nine acquired dispensaries already showing an 11% increase in gross profit dollars compared to pre-acquisition baselines.
-
Cresco Labs Inc ( CRLBF ) maintains leading market positions, holding the number one branded share in Pennsylvania (16%), Illinois, and Massachusetts, with Sunnyside stores generating over 30% more revenue than state averages.
-
The company is well-positioned for federal cannabis reform, with rescheduling expected to eliminate the 280E tax burden, improve net income, and open doors to U.S. exchange listings and cheaper capital.
-
Cresco Labs Inc ( CRLBF ) generated $15 million in operating cash flow in Q2, a significant improvement from a $6 million use in Q1, and continues to invest in growth areas like Kentucky and Ohio.
Negative Points
-
Cresco Labs Inc ( CRLBF ) faces intense competition in Illinois, where increasing vertical integration is shifting the retail landscape and pressuring the market.
-
The company expects Q3 2026 revenue to be roughly flat sequentially, as continued price compression and competition offset growth from new stores and the Kentucky launch.
-
Gross margins are expected to decline to the high 40% to 50% range in the second half of 2026 due to higher-cost inventory and temporary costs from facility upgrades.
-
The company experienced a setback in Texas, where its license application was awarded and then taken away, requiring legal action to recover the license.
-
Cresco Labs Inc ( CRLBF ) announced the departure of its CFO, Sharon Schuler, which introduces leadership transition risk during a critical period of growth and capital markets preparation.
Q & A Highlights
Q: What drove the gross margin expansion in Q2, and how should we think about margin evolution given the Q3 guidance? A: Sharon Schuler (CFO): Q2 benefited from selling through higher-margin products, particularly in Ohio, along with some one-time benefits not expected to repeat. For the back half, we anticipate working through higher-cost inventory tied to facility upgrades, which is factored into our guidance of high 40% to 50% gross margin.
Q: What are your thoughts on the potential impact of pending hemp restrictions on the legal market, and could it be meaningful heading into 2027? A: Charles Bachtel (CEO): It's hard to quantify the exact uplift, but hemp has broadened the consumer base for cannabinoid products. As restrictions take effect, we expect benefits to flow to the regulated channel. Ohio serves as a case study, where enforcement has driven 30% year-over-year growth in the regulated market.
Q: What drove the 11% gross profit dollar lift from the acquired Pennsylvania dispensaries, and how much room is left for further improvement? A: Charles Bachtel (CEO): The lift reflects the strength of our operating team and proven models. This is just phase one; we're excited about phase two when we fully convert stores to the Sunnyside brand and implement our complete operating playbook. Assets are worth more inside the Cresco platform.
Q: Can you provide an update on your license application in Texas and your strategy to participate in that market? A: Charles Bachtel (CEO): We were unfortunately awarded a license and then had it taken away. We're taking appropriate actions to recover it. Texas is an incredibly large state with demonstrated demand, and we'll approach it like every other new market, leveraging our experience in launching and developing markets successfully.
Q: How do you think the valuation re-rating will play out with rescheduling, and what's the best M&A strategy in that environment? A: Charles Bachtel (CEO): It's hard to quantify, but we see greater access to capital as a meaningful catalyst. Investor education will be key as we reintroduce the cannabis story. Greg Butler (President) added that with cheaper capital, we have high torque potential to enter states like New Jersey or Connecticut and invest in areas where we're proving we win.
Q: What are the biggest differentiators that have allowed you to weather the harsh Pennsylvania market, given delays in adult-use transition? A: Charles Bachtel (CEO): We've been in Pennsylvania since the beginning and helped launch the program. Our team on both cultivation and retail sides is experienced and has been with us from the start. Our capability and strength allow us to take advantage of accretive opportunities even when others can't.
Q: Any update on the Pennsylvania legislature standoff regarding adult-use legalization? A: Charles Bachtel (CEO): It's a political issue, and sometimes good policy doesn't make good politics. Recent conversations with legislators on both sides are positive and supportive. It's a matter of how and when, not if, and we'll be successful as an adult-use program when it happens.
Q: What are you seeing on the ground regarding enforcement actions in key states, and how material are those changes? A: Charles Bachtel (CEO): With increased federal focus on cannabinoid products, states are leading on enforcement. This is encouraging for professional, compliance-focused operators. Greater enforcement will eradicate illicit and irresponsible practices, and professional operators will benefit long-term.
Q: Can you provide an update on international shipments and what you've learned about selling internationally? A: Charles Bachtel (CEO): We're encouraged by our initial experiences. Our brands are transportable, and there's recognition of our capabilities. It's a test-and-learn situation, and we remain optimistic about future potential in Europe, though it's not a straight line and requires capability to adjust as markets evolve.
Q: How should we think about the Q3 revenue guidance being roughly in line with Q2? A: Sharon Schuler (CFO): Q3 revenue is expected to be roughly in line with Q2 as we continue ramping the acquired store network and begin generating revenue from Kentucky, offsetting continued price compression and competition. We expect adjusted SG&A to be flat in dollar terms and adjusted EBITDA margins of approximately 20%.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
